Post-Traumatic Stress and Stressor-Related Disorders in Hematological Malignancies: A Review
Посттравматический стресс и расстройства, связанные со стрессорами, при гематологических злокачественных новообразованиях: обзор
2025-08-29
SCID: 54.1/dxvz78xk
Discuss with AI
hematological malignancieshematopoietic stem cell transplantationpost-traumatic stress disordertrauma-informed screeningtreatment adherence
Figures from the paper
Abstract (AI)
Background: Patients with hematological malignancies undergo intensive treatments, endure prolonged hospitalizations, and face the stress of a life-threatening diagnosis, placing them at high risk for developing post-traumatic stress disorder (PTSD) and related trauma symptoms. Methods: This narrative review synthesizes findings from PubMed-indexed studies examining the prevalence, clinical features, and consequences of PTSD in patients with hematological malignancies. A separate focused search was also conducted to identify PTSD studies in patients undergoing hematopoietic stem cell transplantation, which is a population recognized as being at high psychological risk. Results: Evidence indicates that a substantial proportion of these patients develop full or subthreshold PTSD. Key contributing factors include treatment intensity, fear of relapse, and extended hospital stays. PTSD symptoms are linked to reduced treatment adherence, diminished quality of life, and poorer clinical outcomes. Conclusions: Psychiatric care plays a critical role in addressing PTSD in this population. Routine trauma-informed screening, access to evidence-based pharmacologic and psychotherapeutic interventions, and close interdisciplinary collaboration with hematology teams are essential to improving patient outcomes.
Key Findings
1
PTSD symptoms are associated with reduced treatment adherence, diminished quality of life, and poorer clinical outcomes.
2
Patients undergoing hematopoietic stem cell transplantation represent a particularly high psychological-risk group for PTSD and related trauma symptoms.
3
Patients with hematological malignancies face substantial risk of developing full or subthreshold PTSD because of intensive treatments, prolonged hospitalization, and life-threatening diagnoses.
4
Routine trauma-informed screening, evidence-based pharmacologic and psychotherapeutic care, and interdisciplinary collaboration are essential components of PTSD management.
5
Treatment intensity, fear of relapse, and extended hospital stays are identified as key contributors to PTSD symptoms in this population.
Research Object
patients with hematological malignancies, including those undergoing hematopoietic stem cell transplantation
Research Subject
the prevalence, clinical features, contributing factors, and consequences of PTSD and related trauma symptoms
Publication Details
Publication Date
2025-08-29
Journal
Publisher
ISSN
Cited by
4
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest